Bd reports first quarter fiscal 2023 financial results

Execution of bd 2025 strategy delivering consistent and durable performance revenue of $4.6 billion decreased 2.8% as reported and increased 1.7% on a currency-neutral basis revenue from base business (which excludes covid-only diagnostic testing) grew 0.4% as reported, 5.2% currency-neutral gaap and adjusted diluted eps from continuing operations of $1.70 and $2.98, respectively company raises full-year revenue and adjusted eps guidance franklin lakes, n.j. , feb. 2, 2023 /prnewswire/ -- bd (becton, dickinson and company) (nyse: bdx), a leading global medical technology company, today announced results for its first quarter of fiscal 2023, which ended december 31, 2022.
BDX Ratings Summary
BDX Quant Ranking